ApolipoproteinA-I (apo A-I) is the major protein of highdensitylipoprotein.Compellingevidence suggeststhat measurement of concentrationsof apo A-I in serum may be useful in predictingand assessing ischemic heart disease. The followingreview of methods of isolation,charactenzation, and assay of apo A-I has been developedto assessthe possibilityof standardizingapo A-I immunoassays.We consider the properties of apo A-I that have an effect on its quantification,such as self-association,polymorphism,and stabilitycharacteristics.We attempt to review criticallythe various methods presented, but more informationabout the physicochemical propertiesof the protein is required before definitiverecommendationscan be made. protein (4). A significant correlation between serum concentrations of ape A-I and HDL cholesterol has been reported, indicating that ape A-I, a primary gene product, perhaps derived from a precursor protein (5), may be a negative predictor for ischemic heart disease (6-8) and may add to the predictive value of HDL cholesterol (9). Ape A-I is important for cholesterol esterification by virtue of its ability to activate the enzyme lecithin-cholesterol acyltransferase (EC 2.3.1.43) (LCAT), which catalyzes the transfer of a C-2 fatty acid from lecithin to cholesterol (10, 11). Ape A-I and other apelipoproteins, expressed as their concentrations in plasma, as ratios to one another, or as ratios to lipid fractions of lipeprotein, may prove to be powerful predictors of ischemic heart disease (12-15).
These are selected representative publications. bAQes are reported as a ranqe, a mean, or mean ± 1 standard deviation. Ape A-I contains approximately 55% alpha helix, 8% pleated sheet, and 37% random coil; adopts a loosely folded tertiary structure; and self-associates in aqueous solution (24-28). Helix content is increased to about 70% when the protein is associated with phospholipid, as in the HDL particle.
Polymorphism of ape A-I, demonstrated by isoelectric heterogeneity, is in most cases thought to be the result of pest-translational modification. Ape A-I has been separated into four polymorphic forms by isoelectric focusing and into six forms by two-dimensional electrophoresis (5, 29). As observed by isoelectric focusing, ape A-I1, ape A-I2, and ape A-I3 are thought to be the result of sequential de-amidization. Ape A-I4 is distinguished by the presence of isoleucine, though this may represent the presence of a contaminating protein rather than genetic polymorphism. Ape A-I1, ape A-12, and ape A-I3 activate LCAT, whereas ape A-I4 appears to inhibit it (29).
Tangier disease is characterized by a decrease in plasma H1)L and is associated with increased risk for ischemic heart disease and cerebrovascular disease (30-32). Plasma ape A-I and ape A-il concentrations are <5% as great as those of controls (33, 34). The disease is thought to be transmitted as a simple autosomal recessive disorder, controlled at one genetic locus, possibly resulting in inhibited binding of ape A-I to other HDL constituents, and in more rapid ape A
-I degradation (35-37). Ape A-I isolated from patients with Tangier disease reported by Kay et al. (38) is structurally different from normal ape A-I.
Others have reported that plasma isoproteins of ape A-I in patients with Tangier disease are present in different proportions from those of controls. There is thought to be a defect in the conversion of major liver and intestinal isoproteins to the major isoproteins of plasma (39).
An example of true allelism in the case of ape A-I (ape A-I Milano) has been described in a patient with hypertriglyceridemia. Unlike normal ape A-I, ape A-I Milano contains cysteine (40, 41). Ape A-I Milano is metabolized more rapidly than normal ape A-I, as is also the case for ape A-I Tangier (42).
The practical effects of genetic and post-translational polymorphism on the antigenicity of ape A-I need to be considered in the effort to standardize ape A-I immunoassays. Reported differences in secondary structure between the apelipoproteins of hypercholesterolemic monkeys and those of controls must also be taken into account when the assay depends on recognition of conformational epitopes
(43).
A property of ape A-I common to many proteins that needs to be considered in purification procedures is selfassociation. Ape A-I self-associates in a reversible fashion as a function of concentration, temperature, pressure, and (perhaps) ionic strength. Self-association is accompanied by an increase in helical structure, as is observed for lipidapoprotein association. Models for self-association differ, possibly owing to differences in methods and the state of the material examined, e.g., the formation of nondissociating aggregates.
A monomer-dimer-tetramer-octamer model of self-association has been proposed by two laboratories on the basis of equilibrium sedimentation (27, 44). Other models have included a monomer-dimer-tetramer or monomer-dimertrimer-tetramer, again on the basis of equilibrium sedimen-
tation (25). A monomer-dimer-trimer-pentamer has been proposed from results of cross-linking studies (45).
Results of equilibrium sedimentation show ape A-I to be in the monomeric state when in concentrations of less than 0.53 g/L (46). These results have been confirmed by others (25, 44) , although Vitello and Scanu (27) noted self-association at this concentration.
Cross-linking studies demonstrated that 60% of ape A-I was in the monomeric form at a concentration of 0.1 g/L, while at a concentration of 0.5 g/L, only 44% remained in the monomeric form (45). This self-association tendency of apolipoproteins has important implications when one is using purified proteins as tracer, standard, and immunogen in conjunction with the ape A-I immunoassay. Interpretation of results of self-association studies may be complicated by the formation of an oligomer in the process of dissolving lyophilized ape A-I. The oligomer is distinguishable from reversible self-association products in that its dissociation is thought to be irreversible. Because its dissociation is temperature dependent, e.g., requiring 80 h at 30 #{176}C but only 3 mm at 37 #{176}C, the oligomer could be confused with more stable self-association products (47).
Lyophilization at any point after delipidation could result in the formation of aggregates of apo A-I that appear as slowly migrating bands in urealpolyacrylamide-gel electrophoresis, giving the impression that the product has not been sufficiently purified. A comparison of delipidation procedures (59) indicated that HDL peptides of low molecular mass and of very-lowdensity lipoproteins were preferentially solubilized in water-saturated solvent systems, especially in 95% ethanol or ethanol/ether combinations. Extraction of lyophilized material rather than aqueous solutions with an anhydrous mixture of ethanol and ether resulted in retention of nonpolar lipids as well as phospholipids.
Ultracentrifugation.

Sequential
Detergents and tetramethyl urea (TMU) have also been used to delipidate apelipeproteins (70, 71).
A recent review cited the following reasons for less than satisfactory products of delipidation: excess KBr remaining in the lipoprotein solution, dialysis against distilled water instead of 0.15 moltL NaCl, use of organic solvents at temperatures warmer than 0#{176}C, and use of prolonged or high-speed centrifugation in the presence of the original aqueous phase (63) .
These experiences suggest that various solvent mixtures may be used for delipidation of ape A-I, but each step in the process selected must be monitored carefully by testing for the presence of lipids.
Chromatographic separation of apolipoproteins. Ape A-I is usually isolated from other HDL-apoproteins by chromatographic separation or by a combination of separations.
Delipidated HDL proteins are classically separated by use of Sephadex G 200 (6, 46, 72, 73) . Ape A-I elutes as a large peak just before ape A-il, and its trailing edge is usually contaminated with ape A-H. The elution buffer commonly used is Ti-is HC1 (0.1 moWL, pH 8.5) with 6.0 or 8.0 mol of urea per liter. Eluted fractions are dialyzed, to remove urea, against NH4HCO3 (50 mmol!L, pH 8.2), lyophilized, and stored under nitrogen at temperatures below -10 #{176}C.
To purify ape A-I further, investigators have also used an ion-exchange step after gel filtration. Ion-exchange chromatography on DEAE cellulose with a Ti-is starting buffer in the range of 10 to 40 mmolfL, pH 8.0 to 8.2, is used for this. A gradient from approximately 10 to 100 mmol of Tris per liter, pH 8.0, with 6 mol of urea per liter, is applied to the column and peaks are further dialyzed, lyophilized, and stored under nitrogen at -10 #{176}C (24, 27, 74). Ion-exchange chromatography alone has also been used to separate ape A-I from other proteins of HDL (24. 68, 75, 76).
Other gel-filtration media with essentially the same buffers and running conditions used as described above have been alternatives in these separations-for example, Sephadex G-150 or BioGel A0.5m or P-i00, either without or with denaturant (e.g., 5 mol/L guanidine HC1 or 8 mollL urea) (63, 77) . Sephacryl S-200 has been used with guanidine HC1, 3 mol/L (63, 78), and AcA-34 with urea, 6.0 moL'L (19). In all cases, urea solutions should be de-ionized and stored at 4 #{176}C to retard cyanate accumulation, with the resulting carbamylation of protein (79), although use of urea and its attendant problems can be avoided if guanidine HC1 is substituted. A method has been described (16) in which guanidine HC1, 6 mmolfL, is used to free ape A-i from d 1.063-1.021 HDL, followed by dialysis, centrifugation at d 1.21, and chromatography on DEAE Sepharose CL-6B. Ape A-I has also been isolated by preparative isoelectric focusing (80) and by chromatofocusing (81). "High-performance" liquid chromatography has been described in self-association studies of ape A-I and has the potential for rapid isolation of the protein (47) .
Although material satisfactory for use as an immunogen, tracer, and standard has been obtained after one gelifitration step, the number of steps required for purification must be determined by individual laboratories.
Characterization of Apo A-I
In some cases, one or two electrophoretic procedures have been considered sufficient for characterization of isolated protein, e.g., sodium dodecyl sulfate/pelyacrylamide-gel electrophoresis and urealpelyacrylamide-gel electrophoresis (82, 83) . More often, the following procedures-amino acid analysis; immunodiffusion against antisera to ape A-H, ape B, ape E, ape D, ape C, and albumin; the presence of only one band after gel electrophoresis; and, in some cases, characteristic patterns on isoelectric focusing-or some combination of them is considered necessary for confident characterization of ape A-I (20, [84] [85] [86] .
Physicochemical characterization, such as assessment of self-association properties, can also be helpful (87) . Immunological and electrophoretic characterization in addition to amino acid determination appears sufficient
to document the quality of the ape A-I product. Ape A-I mass is commonly evaluated by quantitative measurement of amino acid content, with use of internal standard and normalization with two or more residues. 
Stability of Standards and Samples
Antisera
Antibody for use in immunoassay of ape A-I is usually raised in rabbits or goats in response to immunization with purified ape A-I (6, 33, 53, 93). In one case, antiserum to HDL was studied (53). The antigen in 50 mmol/L NH4HCO3, 150 mmol/L NaC1, or distilled water, in a concentration of 0.5 to 1.5 gIL, is mixed with equal volumes of complete Freund's adjuvant and injected subcutaneously or intramuscularly at multiple sites. Intraperitoneal injection to stimulate antibody synthesis has been used less often. Booster doses, with or without incomplete Freund's adjuvant, are given at two or four weeks and continued until a desired antibody titer is reached. A common immunization schedule includes boosting every two weeks after the initial dose for six weeks, then bleeding eight to 10 days after the last injection (6, 33, 94).
Whole serum or antisera purified to various extents are used in immunoassays for ape A-I. Immunoglobulins precipitated with 2 mol of ammonium sulfate per liter are further purified by ion-exchange chromatography. Affinity chromatography with ape A-I or HDL bound to Sepharose 4B isolates specific antibodies and decreases the background on immunodiffusion (53,95). To obviate cross reactivity, antiserum has also been absorbed with ape A-Il. The greater stability of antibodies in whole serum than in a purified state must be considered before deciding whether to purify antibodies or not. Specificity of antisera is generally determined by immunodiffusion against lipeproteins, apolipeproteins, and serum proteins-specifically against HDL, LDL, ape A-I, ape A-Il, ape C-I, ape C-il, ape C-rn, ape D, ape E, albumin, and whole serum. Immunoelectrophoresis and crossed immunoelectrophoresis are also used to assess the specificity of antiserum (96-98). Demonstration of (a) almost quantitative displacement of labeled ligand by the unlabeled ligand in the assay and (b) the inability of contaminating proteins to displace labeled ligand appreciably also define the specificity of an antiserum that is to be used for RIA.
Monoclonal antibodies to many of the apelipeproteins, including ape A-I, currently are being prepared in several laboratories. These antibodies will probably find their greatest application in immunoassays that involve primary antigen-antibody reactions, such as RIA, and enzyme-or fluorescence-linked assays. Polyclonal antibodies are more appropriate for use in immunoassays that depend on secondary phenomena such as lattice formation, as is the case for EIA, RID, and INA. Monoclonal antibodies are also very sensitive tools for structural studies.
Immunoassay
The more specific methods for quantifying apelipeproteins are the immunochemical methods. Measurement of apelipeproteins is complicated by the fact that in serum they are present as a part of a large, biochemically heterogeneous particle, within which some of the antigemc sites are concealed. Even when the pure peptides are to be assayed, immunoassays have been used, because of their specificity. Although the number of experimental variables is greater in immunoassays than in other quantitative methods, the specificity obtained when assaying in a matrix of many other proteins, often without the need to first purify the analyte, makes immunoassay the most attractive technique for measurement of apolipoproteins. Ideally, the accuracy of a method is evaluated by use of an entirely different method. Currently, however, there is no satisfactory reference method with which to evaluate immunoassays for apolipopro-
teins. Immunoassays
have greater coefficients of variation than do most other analytical procedures. Indeed, the withinassay variation is usually no less than 5%, and betweenassay variation ranges from 10 to 15% (99). This variation results from antibody variability, from multiple assay steps and dilutions, and, particularly with RIA, from variations in specific activity of the tracer and from difficulties encountered in separating bound analyte from free. Between-and within-assay variations appear to be less a problem in the immunoassays for ape A-I (Tables 2-6 ). In immunoassays of apolipoproteins, standards consisting of particle species that are unlike the analyte have been used. Questions remain as to the method of choice of treatment of unknown samples for ensuring that standard and analyte are in a physical state that will give equivalent immunological competition for antibody. Samples have been pretreated by denaturing agents, heat, or delipidating agents (see below) to expose antigenic sites on apolipoproteins in plasma for comparison with purified apelipeprotein standards. Although most workers in the field find that pretreatment of samples is necessary, there is no consensus as to the method that will yield the most nearly accurate results.
A recently suggested and novel approach to obviate the problem of differences in binding between plasma species of apelipoprotein and standards is the use of antibodies to ape A-I surface antigens on the HDL particle (see below). Antibodies raised to isolated ape A-I are passed over d 1 (Table 2 ) was the first immunoassay used for quantifying apelipeproteins (6). Unlike ELA or RID, RIA is a competitive protein-binding assay in which an analyte (ligand) competes with a labeled ligand for antibodies to the unlabeled ligand. The serum analyte must have binding properties that enable it to compete equally with the standard for the antibody, whether or not it is identical to the standard in other ways, i.e., molecular form or charge. This point is especially pertinent in the RIA of apelipoprothins, because ape A-I standards and the ape A-I in serum or plasma often differ in their physical states.
In the determination of apelipeproteins, a second antibody has classically been used to separate total ligand bound to antibody from total free ligand. Radioactivity is then determined in the antibody-bound compartment and compared with that found in systems with standards of known concentrations of unlabeled material. The standards must compete for antibody in a manner equivalent to the analyte present in plasma. A recently described method for the separation step takes advantage of the ability of staphylococcal A antigen to bind the Fc fragment of immunoglobulin.
Killed, intact staphylococci act as a solid-phase absorbent for separation of bound from unbound antigen, a method that requires hours rather than an overnight incubation (as in the case with the second-antibody method) (109). However, staphylococcal A antigen may give better results with rabbit antisera than with goat antisera, owing to the absence of nonreacting subgroups of IgG in rabbits. Using the surfactant Tween 20 in this method obviates high nonspecific binding, which has been a problem in many cases (110).
Sensitivity is in the nanogram range, which can present problems because of errors in dilution steps. Between-and within-assay variations as low as 5% have been reported (Table 2) .
Methods commonly used to iodinate ape A-I are Chloramine T (111, 112), lactoperoxidase (113), and iodine monochloride methods (114). Irrespective of the method used, two pools of radiolabeled ape A-I have been demonstrated to result from iodination. One pool is physically and imniunochemically indistinguishable from native ape A-I; the second pool is physically and immunochemically altered. "High-performance" liquid chromatography has been used to separate the unaltered pool from the second pool (J. C. Osborne, personal communication). Electroimmunoassay (Table 3) has had widespread use; it has most of the advantages of RIA without requiring the use of a radioactive component in the assay. Antigen is quantified by electrophoresis of the antigen into agarose containing its corresponding antibody, a process that results in 0 (8, 102, 105) . The "rockets" are then measured in terms of peak height or area and compared with peaks formed by purified ape A-I as primary standards or dilutions of serum used as secondary standards.
Although reported between-and within-assay coefficients of variation range from 1 to 9%, most workers reported between-assay variation of 5 to 7% and within-assay variation at 5% or less. A sensitivity of about 20 ng can be expected for ape A-I (90).
Studies of sample treatment to expose all antigenic sites have not provided straightforward answers in all cases. In some studies, the use of denaturing agents in the EIA of ape A-I resulted in decreased peak heights (88, 121), but in others the peak height increased after samples were treated with buffers containing TMU or urea (67, 119). In EIA it is important that sample and standards are of the same molecular size and charge (122). Secondary standards such as serum pools are useful in this regard.
Roheim and Vega (121), after treating samples with NP-40 surfactant (10 g/L) and urea (8 moL'L), obtained values for serum ape A-I similar to those others reported by RIA and RID. They believed that decreases in peak heights in the presence of denaturing agents were ascribable to exposure of new antigemc sites reacting with antibody in the agarose that was not recognized by previously exposed antigen. In effect, antibody concentration was increased by exposing these sites. If pretreatment were to expose additional antigemc sites of the type that were already exposed, the antigen concentration would be effectively increased in relation to the antibody concentration and the peak height increased. Heterogeneity of antisera could present problems here, especially in view of the possible variability of exposure of ape A-I antigenic sites.
Radial immunodiffusion (Table 4) provides a simple but reliable method for determining ape A-I in plasma (7). The formation of precipitin rings by diffusion of antibody into an agarose medium containing antibody provides a method by which the antigen can be quantified: antigen concentration is proportional to precipitin ring area. If TMU is used in the diluent, the full complement of plasma ape A-I can be quantified without a prior delipidation step. Heating samples at 52 #{176}C for 3 h is another way to prepare samples for assay by RID. Extraction with ether resulted in lower values than expected (100). The dilutions used, only 10-to 40-fold, make radial immunodiffusion less susceptible to dilution error than RIA, which requires dilutions of iOu-to 104-fold.
Antibody must be specific if multiple precipitin bands are to be avoided in RID. As with EIA, heterogeneity of antisera is a potential problem. The size of the analyte and standard must be roughly equivalent in radial immunodiffusion.
Immunonephelometric assays (Table 5 ) measure the intensity of scatter of an incident light beam, which is proportional to the concentration of antigen-antibody complexes in the solution being assayed. This method has been used in the quantification of serum proteins and now is being used in immunoassays for human ape A-I and ape B (104, 106-108, 118, 119, 123-125) .
Antisera for INA are raised to purified ape A-I. A step designed to expose ape A-I antigenic sites in plasma does not appear to be necessary when serum or plasma of known ape A-I concentration is used to obtain a standard curve (94,
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119).
When isolated ape A-I has been used as standard, dilution of samples with 6 moIJL guanidine HC1 has maximally exposed antigenic sites, thereby affording accurate ape A-I estimation by INA (108). Care must be taken to allow enough time for the guanidine HC1 to dissociate ape A-I from the HDL particle.
INA is well suited to large-scale screening for apolipoproteins and does not require the rigorous technique of the above-mentioned assays (108). The currently used technique requires 20-50 L of serum and quantities of antibody reagent similar to those used in EIA. The lower limit of detection of the assay is approximately 50-100 ng. Withinand between-assay coefficients of variation as low as 2.5 and 6.3% have been reported (94). Funke 
pretreatment to expose antigemc sites, especially in dyslipoproteinemic sera and lipemic sera, are potential problems for RID, ELA, and INA. Binding parameters of the RIA are clearly definable, a purified apolipoprotein is used as a standard, and effects of each component of the assay can be clearly monitored. Its sensitivity makes RIA suitable for use in quantifying ape A-I in specimens other than serum; RIA can be used for serum, though care should be taken to avoid dilution errors.
Pretreatment of Samples to Expose Antigenic Sites
Although there have been reports that RIA and INA can detect most or all of the ape A-I present in serum or plasma without prior treatment of the specimen (53, 90, 94, 119, 124, 127) , many workers agree that it can be more nearly accurately estimated if a step designed to maximize the exposure of antigenic sites is included. HDL-associated ape A-I does not compete equally with isolated ape A-I for binding sites in polyvalent antisera to ape A-I or HDL. Differences in specificities or affinities for the antisera could be responsible for this (84) .
Schonfeld and Pfieger (6) demonstrated that only 5-10% of ape A-I in serum was quantified by RIA when there was no pretreatment of samples, whereas 95% was detected after delipidation.
A later report confirmed this finding (128) . Others have reported detecting most or all of serum apo A-I by RIA and RID when samples were either diluted io-to 107-fold and then heated for 3 h at 52 #{176}C, or partly delipidated with TMU, or treated with Tween-20 (73, 93, 110, 129) .
In RIAs for rat and human ape A-I, 5 and 9 mmolJL sodium dodecyl sulfate, respectively, have been used to expose ape A-I antigenic sites (124, 130) .
A comparison of several methods to expose antigenic sites of ape A-I (108) included delipidation with organic solvents, heating, and treatment with guanidine HC1. A 100-fold dilution of plasma with 6 mollL guanidine HC1 was found to expose antigemc sites and obviate the need for extraction with organic solvents in an INA.
Miller et al. (67) detected amounts of ape A-I equal to those detected after delipidation with ether/ethanol by using 9 molIL urea in barbital buffer in an EIA, but heating plasma at 54 #{176}C for 3 h did not appear to allow detection of all antigenic sites by this assay. Perhaps the discrepancies between the findings of these studies and those above are in some way related to antibody specificity or dilution of antiserum. Plasma was diluted five- this may explain why the latter group obtained higher results.
Soon after the publication of results by Schonfeld and Plleger (6), which demonstrated that without delipidation of plasma only 5 to 10% of ape A-I was detectable by RIA, a report appeared of a double-antibody RIA that measured most plasma ape A-I without prior delipidation (53). These authors (53) speculated that either a 2-h incubation at 37 #{176}C before the overnight 4#{176}C incubation or a "possible difference in the nature of the antibodies" was the factor responsible for these differences in their results and those of Schonfeld and Pfieger. Others also believe that differences in antibody specificity were probably responsible (131).
In the study of Fainaru et al. (53) the full complement of ape A-I in serum was detected without delipidation of HDL, apparently because an HDL antiserum was purified to obtain ape A-I antiserum. This antiserum was enriched in antibodies to surface determinants of HDL-associated ape A-I, that is, the COOH-terminal, and was thus able to react to the same degree with HDL-associated ape A-I as with isolated ape A-I standard. Although antibody to the NH2-terminal of ape A-I may have been present in the HDL antiserum, the antiserum still should be relatively enriched in COOH-terminal antibodies (84) and was probably further enriched by passage over an ape A-I-Sepharose affinity column. Ape A-I was coupled to cyanogen bromide-activated gel by the NH2-terminal portion, thus leaving the COOHterminal free to bind to surface-specific antibodies in the HDL antiserum.
Another recent report (95), which made past results clearer, also describes measurement of most ape A-I in plasma without prior delipidation; in this procedure an antiserum to surface determinants of ape A-I is used. In this case, surface-specific antibodies were separated from antibodies to other determinants along the ape A-I peptide chain by passing heterogeneous anti-ape A-I antibodies over intact HDL contained in the d 1.21 upper centrifugal fraction and coupled to a cyanogen bromide-activated Sepharose 4B column. Again, the resulting antibodies to surface determinants of ape A-I-associated HDL reacted as well with intact HDL as with purified ape A-I.
In summary, the above results indicate that purified standards can be compared with intact HDL in serum in the RIA if an appropriate antibody, i.e., to the surface determinant, is used. Surface determinants may vary with isolation, storage, and other treatment of HDL. If multiple-site reactive antiserum to purified ape A-I is used without further purification, and a purified ape A-I standard is used, a step to expose antigenic sites in the unknown sample is necessary.
Summary on Standardization
Evaluation of serum pools and purified standards for ape A-I content by six specialized centers of research (SCOR) laboratories of National Heart, Lung and Blood Institute revealed reasonable agreement of results from normotriglyceridemic serum (coefficient of variation, 10%). Problems resulting from hypertriglyceridemic serum have been mentioned above. Results obtained from purified standards were more variable than those from serum peels (R. J. Havel, personal communication).
These results and those of studies described in this review indicate that frozen serum pools are currently the best reference material. When problems associated with maintaining purified ape A-I in an immunologically, biochemically, and physically stable form are solved, a purified standard may be introduced.
Fresh preparations of ape A-I purified to homogeneity as judged by amino acid analysis can serve as a standard when prepared in and used by individual laboratories. Serum pools made from "fresh" serum and stored at temperatures below -50 #{176}C appear stable and suitable for calibration and control purposes.
When purified protein standards are used among laboratories in the future, standardization of ape A-I immunoassays may depend on the development of methods that reproducibly and uniformly expose antigemc sites, or on the use of an antiserum that reacts with surface determinants of intact HDL.
We have attempted here to give a background and overview of methods currently being used in the isolation, characterization, and quantification of ape A-I. Many of the problems associated with ape A-I quantification have been mentioned or discussed. Before specific recommendations for the standardization of assays can be made, available meth-ods for pretreatment of serum or plasma, preparation of antisera, and quantification of ape A-I should be compared, with use of well-defined populations.
Standardization resources ultimately needed for ape A-I determinations are (a) a purified standard preparation, (b) a serum pool to be used as a reference, (c) control material that is applicable to all 
